West Bengal ANM GNM Nursing Syllabus plays a vital part in exam preparation. It allows candidates to create a focused ...

OpenAI's latest small reasoning model represents a significant leap forward in AI capabilities. Unlike traditional language ...

Departamento de Ciencias de la Educación, Área de Didáctica de las Ciencias Experimentales, Universidad de Oviedo, C/Aniceto Sela s/n, 33005 Oviedo, Asturias, Spain ...

Primarily, Ascentage hopes to leverage the IPO proceeds to advance its pipeline. Around $50 million to $60 million, for instance, will help the biotech pursue approval for its BCL-2 blocker ...

The biotech firm's mRNA-1018 candidate posted positive results in a Phase 1/2 study launched in 2023. Moderna plans to move mRNA-1018 to a Phase 3 trial. Shares of Moderna (MRNA) took off Tuesday ...

You eat an olive and patiently listen to your date tell you about his job at a bank. Your brain is processing this scene, in part, by breaking it down into concepts. Bar. Date. Martini. Olive. Bank.

Tata Motors isn’t exactly the first name that comes to mind when you think of premium vehicles, but the Avinya X concept, unveiled at Auto Expo 2025 in India, might just change that perception.

Suzuki created a bunch of concepts for the 2025 Bharat Mobility Global Expo in India. The Swift Champions looks like a hot hatch, and the Jimny Conqueror like an overlander. Maruti Suzuki ...

Celebrating two decades of dominance in the premium hatchback segment, the Swift ‘Champions’ Concept blends legacy and innovation. With a bold red finish and racing-inspired decals ...

Keep track of the amount of attention these coins get. Sustained attention over time is more valuable than a quick fad. Appreciating cyclical factors can help with timing purchases and sales.

However, the buzz further intensified with new concepts shown for their existing lineup, one of which is the Maruti Brezza Powerplay concept. Let’s explore how this new concept edition of the ...

Merck's (NYSE:MRK) recent acquisition of rights to Chinese biotech LaNova Medicines' cancer candidate LM-299 in a deal worth up to $3.3B underscores Big Pharma's appetite for best-in-class assets ...